Global Cancer Supportive Care Products Market, By Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, and Granulocyte Colony Stimulating Factor), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Compounding Pharmacies) – Industry Trends and Forecast to 2031.
Cancer Supportive Care Products Market Analysis and Size
The cancer supportive care products market continues to advance with innovative technologies and methods aimed at improving patient quality of life. Recent developments focus on personalized treatments, targeted therapies, and supportive care solutions that mitigate treatment side effects. This market is poised for growth as healthcare providers prioritize comprehensive cancer care, integrating supportive therapies to enhance patient outcomes and well-being.
For instance, According to the World Cancer Research Fund International (WCRF), projections indicate over 24 million global cancer cases by 2035, excluding non-melanoma skin cancer. In 2017, the National Cancer Institute (NIH) reported over 1.5 million new cancer diagnoses in the United States.
The global cancer supportive care products market size was valued at USD 21.14 billion in 2023 and is projected to reach USD 25.76 billion by 2031, with a CAGR of 2.5% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, and Granulocyte Colony Stimulating Factor), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Compounding Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Acacia Pharma Group Plc (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Fagron (Belgium), KYOWA HAKKO BIO CO.,LTD. (Japan), APR (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen Inc. (U.K.), Baxter (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), and GSK Plc (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Cancer supportive care products encompass a range of treatments and aids designed to alleviate symptoms and side effects associated with cancer and its treatments. These include medications for pain management, anti-nausea drugs, wound care supplies, nutritional supplements, and psychological support tools. Their aim is to enhance the quality of life for cancer patients by addressing physical, emotional, and practical challenges during their treatment journey.
Cancer Supportive Care Products Market Dynamics
Drivers
- Increasing Cancer Incidence
The increasing global incidence of cancer has spurred a heightened demand for supportive care products that alleviate treatment-related symptoms and side effects. For instance, medications addressing chemotherapy-induced nausea and pain management therapies have become essential in enhancing patient comfort and treatment adherence. This rising necessity underscores the market's growth as healthcare providers and patients prioritize comprehensive supportive care to improve quality of life during cancer treatment.
- Rising Focus on Patient-Centric Care
The rising focus on patient-centric care models is significantly driving the growth of the cancer-supportive care products market. Healthcare providers increasingly integrate comprehensive supportive care into cancer treatment plans, enhancing patient comfort and quality of life. For instance, programs offering integrated supportive care services, such as pain management, nutrition counseling, and psychological support alongside chemotherapy or radiation therapy, demonstrate the market's responsiveness to patient needs and preferences, thereby expanding market opportunities.
Opportunities
- Supportive Government Initiatives and Healthcare Policies
Supportive government initiatives and healthcare policies create significant opportunities for the cancer supportive care products market by encouraging their adoption and integration into standard care protocols. For instance, policies that subsidize or reimburse costs associated with supportive care products, such as pain management medications or nutritional supplements, can lower barriers to access. This not only enhances patient outcomes but also expands market potential in regions where such policies are implemented effectively.
- Advancements in Cancer Therapies
Technological advancements in cancer therapies, such as targeted therapies and immunotherapies, have significantly improved treatment outcomes. However, these treatments often bring side effects such as nausea, fatigue, and neuropathy. This creates opportunities in the market for supportive care products such as anti-nausea medications, pain relievers, and nutritional supplements. For instance, the development of novel antiemetic drugs has addressed chemotherapy-induced nausea, enhancing patient comfort and quality of life during treatment.
Restraints/Challenges
- Adverse Effects and Safety Concerns
Adverse effects and safety concerns associated with supportive care products in cancer treatment often hinder market adoption. Balancing the benefits of symptom relief with potential risks requires rigorous evaluation and monitoring. Concerns over side effects can deter healthcare providers and patients from using these products, impacting their market penetration and acceptance despite their intended therapeutic benefits.
- Complexity of Clinical Trials
The complexity of clinical trials for cancer supportive care products is hindered by diverse patient populations and subjective endpoints such as quality of life. These factors contribute to prolonged development and approval timelines, slowing market entry.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2022, Imugene, an Australian biotech company, announced a collaboration with MSD (Merck & Co., Inc.) to assess HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD's pembrolizumab (KEYTRUDA) for HER-2 positive gastric cancer patients. The clinical trial aims to evaluate the safety and efficacy of this combination therapy
- In March 2022, Novartis received FDA approval for Pluvicto to treat metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen-positive tumors. This approval applies to patients who have previously undergone androgen receptor pathway inhibition and taxane-based chemotherapy. Pluvicto aims to address advanced stages of this specific type of cancer
- In September 2020, Merck presented over 30 abstracts at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, showcasing advancements in oncology research and treatment strategies across various cancers
- In August 2020, Bristol Myers Squibb reported that Idhifa, approved by the FDA for relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation, did not demonstrate improved survival outcomes when combined with optimal supportive care in late-stage clinical trials for the same patient group
Cancer Supportive Care Products Market Scope
The market is segmented on the basis of drug class, indication and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Nonsteroidal Anti-Inflammatory Drugs
- Anti-Infective
- Anti-Emetics
- Monoclonal Antibodies
- Erythropoietin Stimulating Agents
- Opioid Analgesics
- Bisphosphonates
- Granulocyte Colony Stimulating Factor
Indication
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Leukemia
- Ovary Cancer
- Melanoma Cancer
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Compounding Pharmacies
Cancer Supportive Care Products Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, drug class, indication and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the cancer supportive care products market, driven by biosimilar adoption and higher biologic prices. Increased pharmaceutical R&D will further bolster market growth in the region during the forecast period.
Asia-Pacific is projected to observe significant growth in the cancer supportive care products market due to rising biosimilars adoption and increasing cancer prevalence. The region's focus on mitigating treatment side-effects contributes to anticipated market expansion in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Cancer Supportive Care Products Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Acacia Pharma Group Plc (U.K.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Fagron (Belgium)
- KYOWA HAKKO BIO CO.,LTD. (Japan)
- APR (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Amgen Inc. (U.K.)
- Baxter (U.S.)
- Bayer AG (Germany)
- DAIICHI SANKYO COMPANY, LIMITED. (Japan)
- GSK Plc (U.K.)
SKU-